Mersana Therapeutics Presents Preclinical Data Further Demonstrating Differentiating Aspects of Its ADC Platform Technology at AACR 2018
17 avr. 2018 13h01 HE
|
Mersana Therapeutics, Inc.
Detailed Characterization of Unique DolaLock Technology Enhancements to Drug Efficacy and Tolerability XMT-1522 Demonstrates Synergy in Combination with a Checkpoint Inhibitor CAMBRIDGE, Mass.,...